MedPath

Effects of Pulse Varieties on Blood Vessel Function in Peripheral Artery Disease

Not Applicable
Completed
Conditions
Peripheral Artery Disease
Interventions
Other: Mixed bean (higher amount)
Other: Mixed beans (lower amount)
Other: control foods
Registration Number
NCT01382056
Lead Sponsor
University of Manitoba
Brief Summary

Consumption of a diet containing pulse crops provides flavonoid compounds that will improve vascular function and glycemic control in individuals with Peripheral Artery Disease.

Detailed Description

This is a single site, randomized, controlled, food intervention study designed to explore the effects of pulse types and varieties on blood vessel function in individuals with Peripheral Artery Disease.

Phase One(Acute): To identify relative potency of pulse types (beans,peas, lentils,and chickpeas) for vascular activity in healthy participants and participants with Peripheral Artery Disease. Healthy participants (10) and participants with Peripheral Artery Disease (10) will be asked to consume (in random order) one test food per in-person visit over 5 visits scheduled a minimum of 6 days apart. Vascular responsiveness will be monitored non-invasively by peripheral arterial tonometry before consumption of the test food and 2 hours post food consumption. Blood samples will be collected at the same time intervals for analyses, of vascular, inflammatory, and metabolic markers as well as flavonoids present in the pulses.

Phase Two(Chronic): Chronic 8-week study using mixed beans (pinto, kidney, black, and navy) to determine improvements in vascular function, cardiovascular risk factors, and glycemic control in participants with Peripheral Artery Disease (N=75, 25/group). Participants will be randomly assigned to one of the following three groups: i) foods containing 0.6 cup mixed beans/day consumed 5 days per week (total amount is 3 cups mixed beans per week); or, ii) foods containing 0.3 cup mixed beans/day for 5 days per week); or, iii) pulse-free foods (control) consumed 5 days/week. A total of 3 in-person visits for screening, baseline and final will be required during the 8-week study schedule. Assessments of vascular function, cognitive function, food dietary intake and preferences, flavonoid levels and cardiovascular risk markers in blood and urine, glycemic control, and anthropometrics will be completed at baseline and at 8 weeks.

Phase Three(Follow-Up: An 8-week follow-up assessment with a subset of participants (n=10/group, 3 groups) with Peripheral Artery Disease will be done at 2, 4, and at 8 weeks. Assessments of vascular function, cognitive function, food dietary intake, flavonoid levels and cardiovascular risk markers in blood and urine, glycemic control, and anthropometrics will be completed. These assessments will enable us to determine the length of time the benefits of the pulse consumption are retained.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
62
Inclusion Criteria

Healthy Participants, Acute Phase:

  • Healthy volunteers, male or female, >33 years of age, age matched with PAD participants ± 7 years;
  • BMI 18-30;
  • Glycated hemoglobin < 6.5%;
  • Fasting serum total cholesterol < 4 mmol/L and triglycerides < 2.5 mmol/L;
  • Blood pressure < 140/90 mm Hg;
  • Ankle-brachial Index (ABI) >0.9;
  • Willing to comply with the protocol requirements;
  • Willing to provide informed consent.

Inclusion Criteria, Participants with Peripheral Artery Disease (Acute Phase and Chronic Phase):

  • Male or female, > 40 years of age;
  • Documented Peripheral Artery Disease including those with claudication as defined by an ankle brachial Index of ≤ 0.90; or asymptomatic carotid stenosis of > 50% or confirmed by imaging; or having had a previous intervention for Peripheral Artery Disease or carotid disease;
  • Stable medication profile with no changes required for the past 3 months;
  • Willing to comply with the protocol requirements;
  • Willing to provide informed consent.
Exclusion Criteria

Healthy Participants, Acute Phase:

  • Currently smoking, or smoking within the last 6 months;
  • Clinically diagnosed disease affecting the heart, liver, kidneys, lungs, gastrointestinal, endocrine or blood/immune systems that requires medical treatment;
  • Taking any prescribed medication with the exception of birth control and hormone (estrogen) replacement therapy;
  • Pregnancy;
  • Amputation of upper or lower extremity on both sides;
  • History of severe gastrointestinal reactions or allergies to pulses or ingredients used to prepare the pulse-containing and pulse-free foods.

Exclusion Criteria, Participants with Peripheral Artery Disease (Acute Phase and Chronic Phase):

  • Currently smoking, or smoking within the last 6 months;
  • Type 1 diabetes;
  • Renal failure requiring dialysis;
  • Acute cardiovascular event or medical illness within the past 3 months precluding study participation;
  • Hormone (estrogen) replacement therapy;
  • Amputation of upper or lower extremity on both sides;
  • History of severe gastrointestinal reactions or allergies to pulses or ingredients used to prepare the pulse-containing and pulse-free foods;
  • Currently participating in or having participated in a food study within the last 3 months unless randomized to a control group and consumed no study foods;
  • High pulse consumption (greater or equal to 2 servings per week);
  • Inability to adhere to a regular diet;
  • Additional intake of pulses other than the requirements outlined in the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Mixed beans (higher amount)Mixed bean (higher amount)Participants may be randomized to foods containing 0.6 cup of mixed beans daily 5 times per week for 8 weeks
Mixed beans (lower aomunt)Mixed beans (lower amount)Participants may be randomized to foods containing 0.3 cup of mixed beans daily, 5 times per week for 8 weeks.
Control foodscontrol foodspulse-free control foods consumed daily, 5 days per week for 8 weeks
Primary Outcome Measures
NameTimeMethod
Evaluate individual pulse types and varieties in healthy participants and participants with Peripheral Artery Disease.5-week schedule

Vascular responsiveness will be monitored non-invasively by peripheral arterial tonometry before consumption of the test food and 2 hours post food consumption. Blood samples will be collected at the same time intervals for analyses, of vascular, inflammatory, and metabolic markers as well as flavonoids present in the pulses.

Secondary Outcome Measures
NameTimeMethod
Evaluate the effects of mixed beans to determine improvements in vascular function16 weeks

Ankle brachial index, blood vessel function and claudication onset/walking distance will be measured and compared at the pre/post consumption time points (time 0, Week 8) in participants receiving food items with the most potent pulse variety or the control food items, and in follow-up during the post consumption follow-up phase at Weeks 2,4, and 8. Results of blood samples will be assessed and compared at the same time points for lipids, glucose, insulin, glycated hemoglobin and select markers of vascular function.

Analysis of dietary patterns and nutritional intake, compliance and tolerability before and after consumption of an 8-week diet of mixed beans8 weeks

Dietary patterns and nutritional intake will be assessed at baseline and at Week 8. Participants will undergo an interview to assess compliance and tolerability at various time points (weeks 2, 5, and 8) throughout the 8-week feeding schedule.

Evaluate the effects of mixed beans on cognitive function16 weeks

Data from the cognitive assessments collected at time 0 and Week 8 of the feeding schedule, and in follow-up post consumption at Weeks 2, 4, and 8, will be analyzed according to the statistical guide and recommendations provided with these tests. The cognitive tests that will be administered are: Mini Mental State Examination, Hopkins Verbal Learning, Digit Symbol Similarities Test, and Digit Span.

Trial Locations

Locations (1)

I.H Asper Clinical Research Institute

🇨🇦

Winnipeg, Manitoba, Canada

© Copyright 2025. All Rights Reserved by MedPath